Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's ...

BioCryst Pharmaceuticals (NASDAQ:BCRX) outlined a multi-pronged growth strategy at the JPMorgan Healthcare Conference, ...

Women neurologists of various subspecialties and career stages gathered for the 4th Annual Women in Neurology Conference, hosted by the Women Neurologists Group.

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

Health providers administered 552,135 influenza vaccine doses to kids over 6 months this season, down roughly 5.5% from the ...

Niktimvo™ (axatilimab-csfr) 4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full year 2025 results – – Ended 2025 with ...

Prestige Consumer Healthcare Inc. (the 'Company” or 'Prestige”) (NYSE: PBH) today announced it will issue its fiscal 2026 ...

Precigen, Inc. ( PGEN) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 10:30 AM EST ...

COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones.